(Q46136248)

19 December 2017

title

IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD. (English)

1 reference

19 December 2017

author name string

L M Pratt

1

1 reference

19 December 2017

Y Liu

2

1 reference

19 December 2017

A Ugarte-Torres

3

1 reference

19 December 2017

M Hoegh-Petersen

4

1 reference

19 December 2017

P J Podgorny

5

1 reference

19 December 2017

A W Lyon

6

1 reference

19 December 2017

T S Williamson

7

1 reference

19 December 2017

F M Khan

8

1 reference

19 December 2017

M A Chaudhry

9

1 reference

19 December 2017

A Daly

10

1 reference

19 December 2017

D A Stewart

11

1 reference

19 December 2017

J A Russell

12

1 reference

19 December 2017

A Grigg

13

1 reference

19 December 2017

D Ritchie

14

1 reference

19 December 2017

J Storek

15

1 reference

19 December 2017

language of work or name

English

0 references

publication date

19 November 2012

1 reference

19 December 2017

Bone Marrow Transplantation

published in

1 reference

19 December 2017

volume

48

1 reference

19 December 2017

issue

5

1 reference

19 December 2017

page(s)

722-728

1 reference

19 December 2017

Current challenges in chronic graft-versus-host disease

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Biology and management of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Treatment of chronic graft-versus-host disease in 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Have we made progress in the management of chronic graft-vs-host disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Clinical applications for biomarkers of acute and chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Biomarkers in chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

A biomarker panel for acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Interleukin 15 as a promising candidate for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Role of IL-15 in immune-mediated and infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

7 January 2021

Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

7 January 2021

Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

7 January 2021

High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

7 January 2021

Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

7 January 2021

Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

7 January 2021

Serum cytokine levels after HLA-identical bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

7 January 2021

High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

7 January 2021

Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

7 January 2021

Prevention of graft versus host disease by inactivation of host antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

7 January 2021

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

7 January 2021

The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.210

7 January 2021

Identifiers

DOI

10.1038/BMT.2012.210

1 reference

19 December 2017

Dimensions Publication ID

1010430012

0 references

1 reference

19 December 2017